Jonathan L. Halperin

91.1k total citations · 19 hit papers
305 papers, 35.1k citations indexed

About

Jonathan L. Halperin is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Epidemiology. According to data from OpenAlex, Jonathan L. Halperin has authored 305 papers receiving a total of 35.1k indexed citations (citations by other indexed papers that have themselves been cited), including 254 papers in Cardiology and Cardiovascular Medicine, 82 papers in Internal Medicine and 34 papers in Epidemiology. Recurrent topics in Jonathan L. Halperin's work include Atrial Fibrillation Management and Outcomes (213 papers), Cardiac Arrhythmias and Treatments (116 papers) and Venous Thromboembolism Diagnosis and Management (82 papers). Jonathan L. Halperin is often cited by papers focused on Atrial Fibrillation Management and Outcomes (213 papers), Cardiac Arrhythmias and Treatments (116 papers) and Venous Thromboembolism Diagnosis and Management (82 papers). Jonathan L. Halperin collaborates with scholars based in United States, United Kingdom and Germany. Jonathan L. Halperin's co-authors include Daniel E. Singer, Keith A.A. Fox, Jonathan P. Piccini, Graeme J. Hankey, Christopher C. Nessel, Manesh R. Patel, Kenneth W. Mahaffey, Richard C. Becker, Valentı́n Fuster and Gregory Y.H. Lip and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jonathan L. Halperin

300 papers receiving 33.6k citations

Hit Papers

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fi... 2001 2026 2009 2017 2011 2006 2010 2016 2006 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
    2011 6.6k citations Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine profile →
  2. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
    2006 1.4k citations Gregory W. Albers, Jonathan L. Halperin et al. Stroke profile →
  3. Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
    2010 1.1k citations Gregory W. Albers, Ruth L. Bush et al. Stroke profile →
  4. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
    2016 942 citations Jonathan L. Halperin, Gregory Y.H. Lip et al. New England Journal of Medicine profile →
  5. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
    2006 839 citations Valentı́n Fuster, David S. Cannom et al. Journal of the American College of Cardiology profile →
  6. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
    2010 770 citations Gregory Y.H. Lip, Jonathan L. Halperin et al. Journal of the American College of Cardiology profile →
  7. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
    2011 712 citations Valentı́n Fuster, Jonathan L. Halperin et al. Journal of the American College of Cardiology profile →
  8. Antithrombotic Therapy for Atrial Fibrillation
    2012 697 citations Daniel E. Singer, Sam Schulman et al. profile →
  9. Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
    2001 659 citations Richard Asinger, Jonathan L. Halperin et al. New England Journal of Medicine profile →
  10. 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
    2011 649 citations Valentı́n Fuster, Jonathan L. Halperin et al. Circulation profile →
  11. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
    2003 645 citations Jack Hirsh, Valentı́n Fuster et al. Circulation profile →
  12. Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation
    2014 614 citations Jonathan L. Halperin et al. profile →
  13. Antithrombotic Therapy in Atrial Fibrillation
    2008 569 citations Daniel E. Singer, Gregory W. Albers et al. profile →
  14. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation
    2013 444 citations Jonathan L. Halperin et al. Circulation profile →
  15. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    2011 440 citations Keith A.A. Fox, Jonathan P. Piccini et al. European Heart Journal profile →
  16. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    2014 321 citations Jonathan L. Halperin, Graeme J. Hankey et al. Circulation profile →
  17. Machine learning prediction in cardiovascular diseases: a meta-analysis
    2020 264 citations Chayakrit Krittanawong, Zhen Wang et al. profile →
  18. Atrial Fibrillation and Diabetes Mellitus
    2019 245 citations Jonathan L. Halperin, Jonathan P. Piccini et al. Journal of the American College of Cardiology profile →
  19. Deep learning for cardiovascular medicine: a practical primer
    2019 235 citations Chayakrit Krittanawong, Kipp W. Johnson et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan L. Halperin United States 88 29.0k 9.5k 6.2k 3.9k 3.3k 305 35.1k
Michael D. Ezekowitz United States 75 41.4k 1.4× 13.3k 1.4× 7.7k 1.2× 3.2k 0.8× 3.9k 1.2× 269 47.8k
Stuart J. Connolly Canada 100 42.2k 1.5× 11.2k 1.2× 5.2k 0.8× 2.1k 0.5× 4.6k 1.4× 474 47.0k
Robert G. Hart United States 69 17.9k 0.6× 5.7k 0.6× 8.1k 1.3× 4.5k 1.1× 1.9k 0.6× 226 24.5k
Elaine M. Hylek United States 79 24.3k 0.8× 11.1k 1.2× 4.6k 0.7× 1.4k 0.4× 2.7k 0.8× 252 31.2k
Harry J.G.M. Crijns Netherlands 93 36.3k 1.3× 4.2k 0.4× 3.1k 0.5× 2.2k 0.6× 3.4k 1.0× 605 42.4k
Michael W. Rich United States 70 21.3k 0.7× 2.3k 0.2× 5.0k 0.8× 3.4k 0.9× 2.8k 0.9× 338 29.2k
Basil S. Lewis Israel 52 20.1k 0.7× 6.9k 0.7× 2.9k 0.5× 2.7k 0.7× 8.6k 2.6× 278 28.0k
Manesh R. Patel United States 79 22.4k 0.8× 6.5k 0.7× 3.1k 0.5× 3.2k 0.8× 9.4k 2.8× 545 30.9k
Robert M. Califf United States 90 24.1k 0.8× 6.4k 0.7× 2.9k 0.5× 1.7k 0.4× 7.8k 2.3× 310 30.5k
Deirdre A. Lane United Kingdom 71 22.1k 0.8× 6.8k 0.7× 4.3k 0.7× 1.0k 0.3× 1.4k 0.4× 311 25.6k

Countries citing papers authored by Jonathan L. Halperin

Since Specialization
Citations

This map shows the geographic impact of Jonathan L. Halperin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan L. Halperin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan L. Halperin more than expected).

Fields of papers citing papers by Jonathan L. Halperin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan L. Halperin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan L. Halperin. The network helps show where Jonathan L. Halperin may publish in the future.

Co-authorship network of co-authors of Jonathan L. Halperin

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan L. Halperin. A scholar is included among the top collaborators of Jonathan L. Halperin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan L. Halperin. Jonathan L. Halperin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mannina, Carlo, Andreina Carbone, Eduardo Bossone, et al.. (2025). Impact of Atrial Fibrillation in Patients With Severe Mitral Regurgitation Undergoing Transcatheter Edge‐to‐Edge Repair. Journal of the American Heart Association. 14(15). e042016–e042016.
2.
Goldenberg, Neil A., Sam Schulman, John M. Kittelson, et al.. (2024). Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Journal of Thrombosis and Haemostasis. 23(2). 651–656.
3.
Spyropoulos, Alex C., Mark Goldin, Walter Ageno, et al.. (2022). Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. SHILAP Revista de lepidopterología. 6(3). e177–e183. 1 indexed citations
4.
Krittanawong, Chayakrit, Albert J. Rogers, Kipp W. Johnson, et al.. (2020). Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management. Nature Reviews Cardiology. 18(2). 75–91. 145 indexed citations
5.
Verma, Atul, Rolf Wachter, Peter R. Kowey, et al.. (2019). Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). The American Journal of Cardiology. 124(6). 864–870. 4 indexed citations
6.
Paquette, Miney, Lionel Riou França, Christine Teutsch, et al.. (2019). Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. The American Journal of Cardiology. 125(3). 383–391. 27 indexed citations
7.
Hirsh, Benjamin J., Robert Copeland-Halperin, & Jonathan L. Halperin. (2015). Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism. Journal of the American College of Cardiology. 65(20). 2239–2251. 148 indexed citations
8.
9.
Halperin, Jonathan L., Menno V. Huisman, Hans‐Christoph Diener, et al.. (2015). ANTITHROMBOTIC TREATMENT IN RELATION TO AGE IN PATIENTS WITH NEWLY DIAGNOSED ATRIAL FIBRILLATION IN NORTH AMERICA (GLORIA-AF PHASE II). Journal of the American College of Cardiology. 65(10). A1518–A1518. 2 indexed citations
10.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm. 11(6). 925–932. 55 indexed citations
11.
Cyr, Derek D., Yuliya Lokhnygina, Richard C. Becker, et al.. (2014). OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL. Journal of the American College of Cardiology. 63(12). A371–A371. 2 indexed citations
12.
Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, et al.. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation Heart Failure. 6(4). 740–747. 83 indexed citations
13.
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, et al.. (2012). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 127(2). 224–232. 375 indexed citations
14.
Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2012). Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. Circulation. 126(suppl_21). 6 indexed citations
15.
Camm, A. John, Sana M. Al‐Khatib, Hugh Calkins, et al.. (2012). A proposal for new clinical concepts in the management of atrial fibrillation. American Heart Journal. 164(3). 292–302.e1. 33 indexed citations
16.
Brott, Thomas G., Jonathan L. Halperin, Suhny Abbara, et al.. (2011). 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Stroke. 42(8). e464–540. 135 indexed citations
17.
Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891. 6637 indexed citations breakdown →
18.
Halperin, Jonathan L., et al.. (2010). Warfarin sensitivity genotyping closer to clinical practice. Nature Reviews Cardiology. 7(10). 549–550. 1 indexed citations
19.
Hirsh, Jack, Valentı́n Fuster, Jack Ansell, & Jonathan L. Halperin. (2003). American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.. Journal of the American College of Cardiology. 41(9). 1633–1652. 229 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael D. Ezekowitz Breakdown of academic impact, for papers by Stuart J. Connolly Breakdown of academic impact, for papers by Robert G. Hart Breakdown of academic impact, for papers by Elaine M. Hylek Breakdown of academic impact, for papers by Harry J.G.M. Crijns Breakdown of academic impact, for papers by Michael W. Rich Breakdown of academic impact, for papers by Basil S. Lewis Breakdown of academic impact, for papers by Manesh R. Patel Breakdown of academic impact, for papers by Robert M. Califf Breakdown of academic impact, for papers by Deirdre A. Lane
Rankless by CCL
2026